488 related articles for article (PubMed ID: 15108350)
41. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
42. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines.
Yamamoto S; Tanaka K; Sakimura R; Okada T; Nakamura T; Li Y; Takasaki M; Nakabeppu Y; Iwamoto Y
Anticancer Res; 2008; 28(3A):1585-91. PubMed ID: 18630516
[TBL] [Abstract][Full Text] [Related]
43. Histone deacetylase as therapeutic target in a rodent model of hemorrhagic shock: effect of different resuscitation strategies on lung and liver.
Lin T; Chen H; Koustova E; Sailhamer EA; Li Y; Shults C; Liu B; Rhee P; Kirkpatrick J; Alam HB
Surgery; 2007 Jun; 141(6):784-94. PubMed ID: 17560255
[TBL] [Abstract][Full Text] [Related]
44. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells.
Sato T; Suzuki M; Sato Y; Echigo S; Rikiishi H
Int J Oncol; 2006 May; 28(5):1233-41. PubMed ID: 16596240
[TBL] [Abstract][Full Text] [Related]
45. Chromatin changes induced by lamin A/C deficiency and the histone deacetylase inhibitor trichostatin A.
Galiová G; Bártová E; Raska I; Krejcí J; Kozubek S
Eur J Cell Biol; 2008 May; 87(5):291-303. PubMed ID: 18396346
[TBL] [Abstract][Full Text] [Related]
46. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
Zhang Y; Fatima N; Dufau ML
Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
[TBL] [Abstract][Full Text] [Related]
47. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.
Xu Y; Voelter-Mahlknecht S; Mahlknecht U
Int J Mol Med; 2005 Jan; 15(1):169-72. PubMed ID: 15583844
[TBL] [Abstract][Full Text] [Related]
48. Doxorubicin induces apoptosis with profile of large-scale DNA fragmentation and without DNA ladder in anaplastic thyroid carcinoma cells via histone hyperacetylation.
Rho JH; Kang DY; Park KJ; Choi HJ; Lee HS; Yee SB; Yoo YH
Int J Oncol; 2005 Aug; 27(2):465-71. PubMed ID: 16010429
[TBL] [Abstract][Full Text] [Related]
49. Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET.
Brest P; Gustafsson M; Mossberg AK; Gustafsson L; Duringer C; Hamiche A; Svanborg C
Cancer Res; 2007 Dec; 67(23):11327-34. PubMed ID: 18056459
[TBL] [Abstract][Full Text] [Related]
50. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
51. Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.
Rundall BK; Denlinger CE; Jones DR
Surgery; 2004 Aug; 136(2):416-25. PubMed ID: 15300209
[TBL] [Abstract][Full Text] [Related]
52. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
Mahboobi S; Sellmer A; Höcher H; Garhammer C; Pongratz H; Maier T; Ciossek T; Beckers T
J Med Chem; 2007 Sep; 50(18):4405-18. PubMed ID: 17691763
[TBL] [Abstract][Full Text] [Related]
53. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Imre G; Gekeler V; Leja A; Beckers T; Boehm M
Cancer Res; 2006 May; 66(10):5409-18. PubMed ID: 16707469
[TBL] [Abstract][Full Text] [Related]
54. Effect of the histone deacetylase inhibitor trichostatin a in human peripheral blood lymphocytes as a function of donor age.
Sourlingas TG; Kypreou KP; Topakas GN; Karchilaki IN; Stavropoulos-Giokas C; Sekeri-Pataryas KE
Ann N Y Acad Sci; 2007 Nov; 1119():64-71. PubMed ID: 18056955
[TBL] [Abstract][Full Text] [Related]
55. Effects of the histone deacetylase inhibitor trichostatin A on nuclear texture and c-jun gene expression in drug-sensitive and drug-resistant human H69 lung carcinoma cells.
El-Khoury V; Gomez D; Liautaud-Roger F; Trussardi-Régnier A; Dufer J
Cytometry A; 2004 Dec; 62(2):109-17. PubMed ID: 15517561
[TBL] [Abstract][Full Text] [Related]
56. Differential protein acetylation induced by novel histone deacetylase inhibitors.
Glaser KB; Li J; Pease LJ; Staver MJ; Marcotte PA; Guo J; Frey RR; Garland RB; Heyman HR; Wada CK; Vasudevan A; Michaelides MR; Davidsen SK; Curtin ML
Biochem Biophys Res Commun; 2004 Dec; 325(3):683-90. PubMed ID: 15541343
[TBL] [Abstract][Full Text] [Related]
57. A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells.
Kang MR; Kang JS; Han SB; Kim JH; Kim DM; Lee K; Lee CW; Lee KH; Lee CH; Han G; Kang JS; Kim HM; Park SK
Biochem Pharmacol; 2009 Sep; 78(5):486-94. PubMed ID: 19445901
[TBL] [Abstract][Full Text] [Related]
58. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
[TBL] [Abstract][Full Text] [Related]
59. Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients.
Hsieh YH; Su IJ; Yen CJ; Tsai TF; Tsai HW; Tsai HN; Huang YJ; Chen YY; Ai YL; Kao LY; Hsieh WC; Wu HC; Huang W
Carcinogenesis; 2013 Feb; 34(2):475-85. PubMed ID: 23172669
[TBL] [Abstract][Full Text] [Related]
60. Histone post-translational modifications by HPLC-ESI-MS after HT29 cell treatment with histone deacetylase inhibitors.
Naldi M; Calonghi N; Masotti L; Parolin C; Valente S; Mai A; Andrisano V
Proteomics; 2009 Dec; 9(24):5437-45. PubMed ID: 19834889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
